What we are looking for

At Roche we are looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionise the standard of care. We focus on our main disease therapy areas – oncology and Immuno-oncology, ophthalmology, infectious diseases and neurosciences–as well as looking at opportunities in promising technologies and early-stage collaborations. Beyond the asset, we always look for the right partnership and cultural fit.

We are not looking for compounds that represent marginal improvements compared to the current standard of care. Roche is not interested in biosimilar compounds or compounds that do not have the potential to become first-in-class or best-in-class.

Please click below for more detailed information on what we are looking for:

Strategic Partnering

Within the organisation, the Strategic Partnering team evaluates a range of deal types including mergers and acquisitions (M&A); alliances covering more than one therapeutic area; out partnering of late stage assets; and in-licensing opportunities that do not fall within Roche’s key therapy areas of interest.

The Strategic Partnering team works closely with Disease Therapy Area heads, to provide expertise on M&A deals.